Highlights
- Market Cap
- $4.64B
- Enterprise Value
- $4.66B
- EPS (TTM)
- -$0.45
- Total Revenue (TTM)
- $521.31M
- Gross Profit (TTM)
- $493.34M
- EBITDA (TTM)
- $40.41M
- Year Range
- $36.88 - $109.28
- Target Price
- $112.60
- ROA (TTM)
- -2.77%
- ROE (TTM)
- -7.42%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Mirum Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Mirum Pharmaceuticals, Inc. (MIRM) has returned 16.95% so far this year and 105.06% over the past 12 months.
Mirum Pharmaceuticals, Inc.
- 1D
- 5.10%
- 1M
- 0.10%
- YTD
- 16.95%
- 6M
- 26.01%
- 1Y
- 105.06%
- 3Y*
- 56.68%
- 5Y*
- 35.00%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Jul 18, 2019, MIRM's average daily return is +0.21%, while the average monthly return is +5.09%. At this rate, your investment would double in approximately 1.2 years.
Historically, 53% of months were positive and 47% were negative. The best month was Dec 2019 with a return of +240.1%, while the worst month was Jan 2020 at -35.9%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 3 months.
On a daily basis, MIRM closed higher 51% of trading days. The best single day was Dec 16, 2019 with a return of +111.0%, while the worst single day was Dec 15, 2020 at -22.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 30.67% | -10.59% | 0.10% | 16.95% | |||||||||
| 2025 | 18.21% | -2.68% | -5.30% | -3.55% | 2.32% | 14.46% | 1.55% | 42.94% | -0.76% | -0.90% | 0.55% | 8.13% | 91.03% |
| 2024 | -10.37% | 8.50% | -12.50% | -0.04% | -4.30% | 42.28% | 18.60% | 6.31% | -9.53% | -1.38% | 20.18% | -10.54% | 40.07% |
| 2023 | 20.41% | 0.13% | 2.17% | 11.78% | -2.31% | -1.37% | -0.43% | 2.60% | 19.56% | -13.20% | 16.92% | -7.95% | 51.38% |
| 2022 | 19.44% | 24.41% | -7.09% | 7.99% | -1.64% | -16.80% | 28.98% | -0.48% | -15.89% | 7.33% | -17.29% | 4.56% | 22.26% |
| 2021 | 3.78% | 1.32% | 7.95% | -1.41% | -15.35% | 4.53% | -16.43% | 12.46% | 22.58% | -20.28% | -10.39% | 12.09% | -8.65% |
Benchmark Metrics
Mirum Pharmaceuticals, Inc. has an annualized alpha of 48.76%, beta of 0.96, and R² of 0.07 versus S&P 500 Index. Calculated based on daily prices since July 19, 2019.
- This stock captured 171.92% of S&P 500 Index gains but only 89.00% of its losses — a favorable profile for investors.
- R² of 0.07 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 48.76%
- Beta
- 0.96
- R²
- 0.07
- Upside Capture
- 171.92%
- Downside Capture
- 89.00%
Return for Risk
Risk / Return Rank
MIRM ranks 92 for risk / return — in the top 92% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Mirum Pharmaceuticals, Inc. (MIRM) and compare them to a chosen benchmark (S&P 500 Index).
| MIRM | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 2.43 | 0.90 | +1.54 |
Sortino ratioReturn per unit of downside risk | 2.96 | 1.39 | +1.57 |
Omega ratioGain probability vs. loss probability | 1.41 | 1.21 | +0.20 |
Calmar ratioReturn relative to maximum drawdown | 4.91 | 1.40 | +3.51 |
Martin ratioReturn relative to average drawdown | 12.85 | 6.61 | +6.24 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore MIRM risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Mirum Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Mirum Pharmaceuticals, Inc. was 63.78%, occurring on Mar 18, 2020. Recovery took 100 trading sessions.
The current Mirum Pharmaceuticals, Inc. drawdown is 14.95%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -63.78% | Dec 30, 2019 | 55 | Mar 18, 2020 | 100 | Aug 10, 2020 | 155 |
| -53.69% | Aug 12, 2019 | 72 | Nov 20, 2019 | 17 | Dec 16, 2019 | 89 |
| -50.92% | Aug 11, 2020 | 329 | Nov 29, 2021 | 89 | Apr 6, 2022 | 418 |
| -40.25% | Aug 8, 2022 | 99 | Dec 27, 2022 | 115 | Jun 13, 2023 | 214 |
| -33.02% | Apr 18, 2022 | 50 | Jun 28, 2022 | 27 | Aug 5, 2022 | 77 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Mirum Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Mirum Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for MIRM relative to other companies in the Biotechnology industry. Currently, MIRM has a P/S ratio of 9.3. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for MIRM in comparison with other companies in the Biotechnology industry. Currently, MIRM has a P/B value of 14.7. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |